-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Financial Comparison: Lisata Therapeutics (NASDAQ:LSTA) and Progyny (NASDAQ:PGNY)
Financial Comparison: Lisata Therapeutics (NASDAQ:LSTA) and Progyny (NASDAQ:PGNY)
Lisata Therapeutics (NASDAQ:LSTA – Get Rating) and Progyny (NASDAQ:PGNY – Get Rating) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, valuation, profitability and analyst recommendations.
Valuation & Earnings
This table compares Lisata Therapeutics and Progyny's revenue, earnings per share (EPS) and valuation.
Get Lisata Therapeutics alerts:Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Lisata Therapeutics | N/A | N/A | -$27.47 million | ($12.23) | -0.20 |
Progyny | $500.62 million | 5.71 | $65.77 million | $0.42 | 73.33 |
Progyny has higher revenue and earnings than Lisata Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
6.0% of Lisata Therapeutics shares are held by institutional investors. Comparatively, 86.1% of Progyny shares are held by institutional investors. 2.2% of Lisata Therapeutics shares are held by company insiders. Comparatively, 14.0% of Progyny shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.Profitability
This table compares Lisata Therapeutics and Progyny's net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Lisata Therapeutics | N/A | -29.53% | -27.96% |
Progyny | 6.00% | 14.14% | 9.62% |
Analyst Ratings
This is a breakdown of recent recommendations for Lisata Therapeutics and Progyny, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Lisata Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
Progyny | 0 | 0 | 3 | 0 | 3.00 |
Lisata Therapeutics currently has a consensus target price of $15.00, suggesting a potential upside of 500.00%. Progyny has a consensus target price of $54.33, suggesting a potential upside of 76.41%. Given Lisata Therapeutics' higher possible upside, equities analysts plainly believe Lisata Therapeutics is more favorable than Progyny.
Risk & Volatility
Lisata Therapeutics has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500. Comparatively, Progyny has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500.
Summary
Progyny beats Lisata Therapeutics on 11 of the 12 factors compared between the two stocks.
About Lisata Therapeutics
(Get Rating)
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
About Progyny
(Get Rating)
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Receive News & Ratings for Lisata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lisata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Lisata Therapeutics (NASDAQ:LSTA – Get Rating) and Progyny (NASDAQ:PGNY – Get Rating) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, valuation, profitability and analyst recommendations.
利薩塔治療公司(納斯達克:LSTA-GET評級)和普吉尼(納斯達克:PGNY-GET評級)都是醫療公司,但哪項業務更優越?我們將根據這兩家公司的風險、機構所有權、收益、股息、估值、盈利能力和分析師的建議來比較它們的實力。
Valuation & Earnings
估值與收益
This table compares Lisata Therapeutics and Progyny's revenue, earnings per share (EPS) and valuation.
此表比較了李薩塔治療公司和Progyny公司的收入、每股收益(EPS)和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Lisata Therapeutics | N/A | N/A | -$27.47 million | ($12.23) | -0.20 |
Progyny | $500.62 million | 5.71 | $65.77 million | $0.42 | 73.33 |
總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
利薩塔治療公司 | 不適用 | 不適用 | -2,747萬元 | ($12.23) | -0.20 |
孕期 | 5.062億美元 | 5.71 | 6,577萬美元 | $0.42 | 73.33 |
Progyny has higher revenue and earnings than Lisata Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.
Progyny的收入和收益比李薩塔治療公司高。利薩塔治療公司的市盈率低於Progyny,這表明它目前是兩隻股票中更負擔得起的一隻。
Insider and Institutional Ownership
內部人與機構持股
Profitability
盈利能力
This table compares Lisata Therapeutics and Progyny's net margins, return on equity and return on assets.
下表比較了李薩塔治療公司和Progyny公司的淨利潤率、股本回報率和資產回報率。
Net Margins | Return on Equity | Return on Assets | |
Lisata Therapeutics | N/A | -29.53% | -27.96% |
Progyny | 6.00% | 14.14% | 9.62% |
淨利潤率 | 股本回報率 | 資產回報率 | |
利薩塔治療公司 | 不適用 | -29.53% | -27.96% |
孕期 | 6.00% | 14.14% | 9.62% |
Analyst Ratings
分析師評級
This is a breakdown of recent recommendations for Lisata Therapeutics and Progyny, as provided by MarketBeat.com.
這是由MarketBeat.com提供的關於李薩塔治療和預後的最近建議的細目。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Lisata Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
Progyny | 0 | 0 | 3 | 0 | 3.00 |
銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
利薩塔治療公司 | 0 | 0 | 2 | 0 | 3.00 |
孕期 | 0 | 0 | 3 | 0 | 3.00 |
Lisata Therapeutics currently has a consensus target price of $15.00, suggesting a potential upside of 500.00%. Progyny has a consensus target price of $54.33, suggesting a potential upside of 76.41%. Given Lisata Therapeutics' higher possible upside, equities analysts plainly believe Lisata Therapeutics is more favorable than Progyny.
利薩塔治療公司目前的共識目標價為15美元,暗示潛在上漲500.00%。Progyny的共識目標價為54.33美元,暗示潛在上行空間為76.41%。鑑於李薩塔治療公司更有可能的上行空間,股票分析師顯然認為利薩塔治療公司比Progyny更有利。
Risk & Volatility
風險與波動性
Lisata Therapeutics has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500. Comparatively, Progyny has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500.
利薩塔治療公司的貝塔指數為0.97,這意味着其股價的波動性比標準普爾500指數低3%。相比之下,Progyny的貝塔係數為1.55,這意味着其股價的波動性比標準普爾500指數高55%。
Summary
摘要
Progyny beats Lisata Therapeutics on 11 of the 12 factors compared between the two stocks.
在兩隻股票之間的12個因素中,Progyny在11個因素上擊敗了李薩塔治療公司。
About Lisata Therapeutics
關於李薩塔治療公司
(Get Rating)
(獲取評級)
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
利薩塔治療公司是一家臨牀階段的生物製藥公司,專注於開發細胞療法並將其商業化,以逆轉疾病和/或促進受損組織的再生。它的候選產品包括接受Sakigake指定的HONEDRA,用於治療嚴重肢體缺血的第二階段臨牀試驗;XOWNA,用於治療冠狀動脈微血管功能障礙的第二階段臨牀試驗;以及CLBS201,一種用於治療慢性腎臟疾病透析前患者的CD34+細胞療法。該公司前身為NeoStem,Inc.,並於2015年6月更名為Caladrius Biosciences,Inc.。該公司前身為Caladrius Biosciences,Inc.,並於2022年9月15日更名為李薩塔治療公司。利薩塔治療公司成立於1980年,總部設在新澤西州的巴斯金裏奇。
About Progyny
關於Progyny
(Get Rating)
(獲取評級)
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Progyny,Inc.是一家福利管理公司,專門為美國僱主提供生育和家庭建設福利解決方案。其生育福利解決方案包括差異化福利計劃設計、個性化禮賓式會員支持服務和有選擇的生育專家網絡。該公司還提供Progyny Rx,這是一種綜合藥房福利解決方案,為其成員提供治療期間所需的藥物。此外,它還為僱主提供代孕和領養補償計劃。該公司前身為Auxogyn,Inc.,並於2015年更名為Progyny,Inc.。Progyny,Inc.成立於2008年,總部設在紐約。
Receive News & Ratings for Lisata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lisata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《利薩塔治療日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊,接收最新新聞和分析師對李薩塔治療公司和相關公司評級的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧